Aliskiren targets multiple systems to alleviate cancer cachexia

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cancer cachexia is a debilitating syndrome characterized by involuntary weight loss, muscle wasting, and systemic inflammation.
• The renin-angiotensin system (RAS) plays a role in cancer cachexia pathogenesis.
• Small-molecule renin inhibitors like aliskiren offer potential therapeutic strategies.

Purpose of the Study:

• To investigate the efficacy of aliskiren in mitigating cancer cachexia.
• To elucidate the molecular mechanisms underlying aliskiren's anti-cachexia effects.

Main Methods:

• A C26 colon carcinoma mouse model was used to induce cancer cachexia.
• Aliskiren was administered either preventively or therapeutically.
• Body weight, tumor growth, muscle function, and survival were monitored.
• Molecular analyses included assessment of RAS activation, inflammation, oxidative stress, autophagy-lysosome pathway (ALP), and ubiquitin-proteasome pathway (UPP).

Main Results:

• Aliskiren significantly reduced body weight loss, tumor burden, muscle wasting, and improved survival in cachectic mice.
• Aliskiren inhibited cachexia-induced RAS activation, systemic and muscular inflammation, oxidative stress, and ALP/UPP stimulation.
• Preventive administration of aliskiren demonstrated more pronounced effects than therapeutic administration.

Conclusions:

• Aliskiren exhibits potent anti-cachexia activities.
• Aliskiren targets multiple mechanisms involved in cachexia, including RAS activation, inflammation, oxidative stress, and protein degradation pathways (ALP and UPP).
• Early intervention with aliskiren is more effective in managing cancer cachexia.